

COVID-19 Patent Wars: mRNA and Lipid Nanoparticle Pioneers Clash over Vaccine Delivery Patents

Authored by Dan Shores for ABA Landslide® Magazine
Article
9.28.22

Partner Dan Shores authored an article titled "COVID-19 Patent Wars: mRNA and Lipid Nanoparticle Pioneers Clash over Vaccine Delivery Patents" for the American Bar Association's (ABA) Landslide® September/October 2022 magazine, Volume 15 Issue 1.

While the COVID-19 pandemic has caused widespread tragedy for millions of families worldwide, it has also spurred concomitant advancements in health care, not the least of which include the first-ever regulatory approvals of therapies based on messenger ribonucleic acid (mRNA) technology. The two leading COVID-19 vaccines on the market, introduced by Moderna Inc. and BioNTech SE (in collaboration with Pfizer Inc.), are based on this technology and are currently the subject of major patent litigations relating to how those therapies are delivered. The article provides an overview of these cases and the current patent litigation landscape in the mRNA space.

Landslide® magazine is dedicated to the sharing of intellectual property knowledge and experience acquired on the front lines of practice, business, and the arts and sciences. The magazine explores national and international arenas and tracks intellectual property law as it gathers momentum in response to the technological, economic, and political transformations of the day.

To read Dan's article, click on the PDF below, or visit the ABA website (accessible to ABA-IPL members only).

Key Contact

Daniel L. Shores

Technologies

Biotechnology & Genetic Engineering